Targeted drug delivery by nanomaterials has been extensively investigated as an effective strategy to surmount obstacles in the conventional treatment of cancer and infectious diseases, such as systemic toxicity, low drug efficacy, and drug resistance. Mannose‐binding C‐type lectins, which primarily include mannose receptor (MR, CD206) and dendritic cell‐specific intercellular adhesion molecule‐3‐grabbing non‐integrin (DC‐SIGN), are highly expressed on various cancer cells, endothelial cells, macrophages, and dendritic cells (DCs), which make them attractive targets for therapeutic effect. Mannosylated nanomaterials hold great potential in cancer and infection treatment on account of their direct therapeutic effect on targeted cells, modulation of the tumor microenvironment, and stimulation of immune response through antigen presentation. This review presents the recent advances in mannose‐based targeted delivery nanoplatforms incorporated with different therapies in the biomedical field.

中文翻译：

---

甘露糖功能化的纳米支架，用于生物医学应用中的靶向递送。

纳米材料的靶向药物递送已被广泛研究，作为克服常规治疗癌症和传染性疾病（例如全身毒性，药物疗效低和耐药性）中障碍的有效策略。结合甘露糖的C型凝集素主要包括甘露糖受体（MR，CD206）和树突状细胞特异性细胞间粘附分子3夺取非整联蛋白（DC-SIGN），在各种癌细胞，内皮细胞，巨噬细胞和树突状细胞（DC），使其成为具有治疗效果的诱人靶标。甘露糖基化的纳米材料由于其对靶细胞的直接治疗作用，肿瘤微环境的调节以及通过抗原呈递的刺激而产生免疫反应，因此在癌症和感染治疗中具有巨大的潜力。